Vertex Pharmaceuticals Incorporated VRTX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -40.57% | 6.63% | -13.41% | 9.99% | 4.84% |
| Total Depreciation and Amortization | 22.48% | 1.07% | 128.16% | -54.63% | 4.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -27.71% | -12.49% | -51.71% | 541.24% | -137.30% |
| Change in Net Operating Assets | -22.17% | -147.00% | 125.82% | -733.56% | 212.99% |
| Cash from Operations | -42.86% | -21.20% | 186.77% | -59.88% | 15.68% |
| Capital Expenditure | 13.28% | 15.89% | 10.71% | -46.76% | 30.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4,507.98% | 122.24% | -115.21% | -812.50% | 95.51% |
| Cash from Investing | -13,220.09% | 89.40% | -49.91% | -146.24% | 75.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -51.99% | 76.67% | -50.00% | 583.54% | -83.91% |
| Repurchase of Common Stock | 56.52% | 16.20% | -331.93% | 88.74% | -192.21% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2,700.00% | -50.00% | -136.36% | 466.67% | 50.00% |
| Cash from Financing | 1,107.01% | 20.81% | -597.93% | 93.31% | -230.61% |
| Foreign Exchange rate Adjustments | -32.43% | 90.82% | -652.05% | 278.05% | -107.17% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -279.53% | 55.65% | 197.93% | 509.36% | -111.53% |